Surrozen reports FY2022 net loss of $36M; cash runway into H2 2024

Surrozen, Inc./DE

Net loss for FY2022 was $36.0M vs $54.6M in FY2021; collaboration revenue $12.5M from Boehringer Ingelheim deal.
Cash, equivalents and marketable securities $75.8M as of Dec 31, 2022, down from $123.5M a year ago.
Restructuring reduces operating expenses by ~15% in 2023; cash runway extends into second half of 2024.
SZN-043 Ph1a enrolled first chronic liver disease patient, data expected end 2023; SZN-1326 Ph1a to reinitiate mid-2023.
Repurchased 5.38M shares and 1.31M warrants from Consonance for ~$2.7M; Consonance no longer holds shares.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Surrozen, Inc./DE reported the year ended December 31, 2022 results: revenue $12.5 million.

Period: the year ended December 31, 2022
Revenue: $12.5 million
Result: reported results

Exact text from the filing

Collaboration and License Revenue for the fourth quarter and year ended December 31, 2022, was $12.5 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Surrozen, Inc./DE reported the fourth quarter ended December 31, 2022 results: revenue $12.5 million.

Period: the fourth quarter ended December 31, 2022
Revenue: $12.5 million
Result: reported results

Exact text from the filing

Collaboration and License Revenue for the fourth quarter and year ended December 31, 2022, was $12.5 million

View on SEC.gov

Browse all earnings releases →

Surrozen, Inc./DE filing history →

Source: SEC EDGAR

accession 0000950170-23-009202

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.